Key result
Aspirin exposure (≥500 mg) completely suppressed platelet aggregation differences across the brain and sodium arachidonate aggregation in patients with chronic ischemic cerebrovascular disease.
Why the study?
Does oral aspirin reduce platelet hyperaggregability in patients in the chronic stage of ischemic cerebrovascular disease?
Observational (n=24)
Does oral aspirin reduce platelet hyperaggregability in patients in the chronic stage of ischemic cerebrovascular disease?
Aspirin suppresses platelet hyperaggregability across the brain in patients with chronic ischemic cerebrovascular disease, supporting its prophylactic use.
May support aspirin for platelet suppression in chronic ischemic cerebrovascular disease; hypothesis-generating and requires randomized outcome trials.
Platelet aggregation was studied in 24 patients in the chronic stage of ischemic cerebrovascular disease (CVD), with cerebral affluent and effluent blood, i.e., carotid arterial and internal jugular venous blood, and also with peripheral venous blood. Aggregation tests were performed at various final concentrations of sodium arachidonate (A.A.) and ADP. In 17 patients, not taking aspirin, platelet aggregability in jugular venous blood was significantly accentuated compared with that in arterial and peripheral venous blood. This tendency was more marked in the patients with cerebral artery stenosis and/or occlusion than in those with normal cerebral angiogram. In 7 patients taking 500 mg or more oral aspirin, aggregation differences across the brain were not observed and A.A. aggregation and the second phase of ADP aggregation were completely suppressed. These results suggest that a prophylactic administration of aspirin may be beneficial for patients in chronic stage of CVD.
No takes yet. Share an insight, caveat, or question.
Kusunoki et al. (1982) conducted an observational in Ischemic cerebrovascular disease (n=24). Aspirin vs. Not taking aspirin was evaluated on Platelet aggregation differences across the brain (jugular venous vs arterial and peripheral venous blood). Aspirin exposure (≥500 mg) completely suppressed platelet aggregation differences across the brain and sodium arachidonate aggregation in patients with chronic ischemic cerebrovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: